首个减量6微克全病毒粒铝佐剂季节性流感疫苗的许可:一项随机对照多中心试验
该多中心随机双盲活性对照非劣效试验纳入1206名成人及老年人,比较含6微克血凝素的全病毒粒铝佐剂三价流感疫苗与已许可15微克疫苗的免疫原性和安全性。结果显示6微克疫苗在两组均安全且非劣效于15微克疫苗,满足FDA和EMEA免疫原性标准及许可要求,并已在匈牙利获批使用。
要点
- 6微克血凝素全病毒粒铝佐剂流感疫苗在成人和老年人中安全且免疫原性非劣效于15微克疫苗。
- 该疫苗满足FDA和EMEA的血清转化、血清保护及GMT比值标准,并符合两组许可要求。
- 减少血凝素含量并辅以磷酸铝佐剂的全病毒粒疫苗可提高生产能力。
核心结论
- 含6微克血凝素的全病毒粒铝佐剂季节性流感疫苗在成人和老年人中安全且非劣效于已许可的15微克疫苗。
研究设计与样本
- 多中心、分层(18-60岁和>60岁)、前瞻性、随机、双盲、活性对照、平行组、非劣效临床试验,在欧盟开展,涉及1206名患者。
主要发现
- 6微克疫苗在成人和老年患者中均安全,且根据FDA和EMEA免疫原性标准(血清转化、血清保护和接种后/前GMT比值)非劣效于15微克疫苗。
- 6微克疫苗满足两个年龄组所有适用的许可要求。
关键数值与推荐
- 采用血凝抑制试验评估免疫原性,免疫原性标准包括血清转化、血清保护和接种后/前GMT比值。
临床怎么用
- 使用全病毒粒疫苗配合磷酸铝佐剂可减少所需病毒血凝素量,有助于提高流感疫苗产能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Shortages of vaccine supplies repeatedly occur, limiting our abilities to prevent influenza. Therefore, increasing production volume remains a priority. The presently licensed seasonal influenza vaccines contain 15 µg of viral hemagglutinin per strain in adult, and up to 60 µg in elderly patients. Decreasing the amount of viral parts while maintaining efficacy is one way of increasing production capacity. METHODS: This was multicenter, stratified (18-60 years and >60 years of age), prospective, randomized, double-blind, active-controlled, parallel-arm, non-inferiority clinical trial, conducted in the European Union, involving 1206 patients. We used hemagglutination inhibition assay to assess the immunogenicity of a newly developed, whole virion, seasonal trivalent influenza vaccine, containing 6 µg hemagglutinin per strain (FluArt, Hungary) and to assess whether it is non-inferior to the presently licensed vaccine containing 15 µg hemagglutinin per strain. Safety and tolerability of both vaccines were assessed based on EMEA guidelines. RESULTS: The reduced dose vaccine containing 6 µg of hemagglutinin per strain was safe and non-inferior to the currently licensed 15 µg vaccine, not only in adult, but also in elderly patients, according to the immunogenicity criteria by the FDA and EMEA (seroconversion, seroprotection and post/pre vaccination GMT ratios), and it fulfilled all applicable licensing requirements for both age groups. CONCLUSIONS: Based on the results, the reduced dose vaccine was licensed in the EU member state Hungary and safely administered in over 1.5 million cases so far. The amount of viral hemagglutinin needed can be reduced by using a whole virion vaccine with aluminum phosphate adjuvants. REGISTRATION: This study was registered by the European Clinical Trials Database, EudraCT, number: 2011-003314-16.
引用
- Vajo Z, Kalabay L, Vajo P, et al. Licensing the first reduced, 6 µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine - A randomized-controlled multicenter trial. Vaccine. 2018. PMID: 30497837. doi:10.1016/j.vaccine.2018.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。